IPCALABBSEIpca Laboratories LtdHighPositive
Announced Fri, 29 May · 14:03 IST

Recommendation of Dividend

Corporate Actions View source PDF

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.9%1-day move
₹1570.10
prior close
₹1571.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.8-0.7+1.7-5.9-3.9-1.2+3.2+4.9+4.1+1.3+4.6
Up moveDown movePending
AI summary

Ipca Laboratories Board has recommended a dividend of Rs. 6 per share (600% on face value of Re. 1) for FY 2025-26, subject to shareholder approval at the ensuing AGM. The record date for dividend entitlement is fixed for August 7, 2026. For the year, standalone revenue grew 10% to Rs. 7,337 Crores while consolidated revenue rose 8% to Rs. 9,646 Crores. Standalone net profit jumped 74% to Rs. 1,133 Crores and consolidated net profit increased 55% to Rs. 1,141 Crores. EPS improved significantly to Rs. 44.64 (standalone) from Rs. 25.65. The Board also re-appointed Mr. Prashant Godha as Executive Director for 5 years.

Likely market impact

Strong profit growth supports the generous dividend payout. Shareholders should benefit from a likely positive market reaction given the robust earnings performance, though the actual yield depends on current market price.